Elicio opens Phase 1 neoadjuvant ELI-002 7P trial in resectable pancreatic cancer at MSK

PUBT · 1d ago
Elicio opens Phase 1 neoadjuvant ELI-002 7P trial in resectable pancreatic cancer at MSK
  • Elicio opened an investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P in resectable or borderline resectable KRAS-mutant pancreatic cancer.
  • Study run by Memorial Sloan Kettering, funded by The Lustgarten Foundation with Break Through Cancer; planned enrollment of 20 patients.
  • Design tests ELI-002 7P with mFOLFIRINOX, with or without anti-PD-1 tislelizumab, starting pre-surgery and continuing post-surgery.
  • No new results were presented; the trial is intended to assess immune activation and potential to improve surgical outcomes and long-term survival.
  • Program builds on prior observations of complete responses in metastatic pancreatic cancer patients treated sequentially with ELI-002 7P, checkpoint inhibition, chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806289) on August 10, 2026, and is solely responsible for the information contained therein.